吉利德 JPM 2025.pdf

1、Gilead in 2025J.P.M or g a n H ea l t hc a r e C onfer enc e1 3 J a nua r y 2 0 2 5Forward-Looking StatementsStatements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Gilead cau

2、tionsreaders that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially.These risks and uncertainties include those relating to:Gileads ability to achieve its anticipated full year 2024 financial results,including as a result o

3、f the uncertainty of the amount and timing of Veklury sales;Gileads ability to achieve its projectedfinancial objectives beyond 2024;Gileads ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy;Gileads ability to accelerate or sustainr

4、evenues for its virology,oncology and other programs;Gileads ability to realize the potential benefits of acquisitions,collaborations or licensing arrangements,including Gileads ability to identifysuitable transactions as partof its business strategy and the risk that Gilead may notbe able to comple

5、te any such transaction in a timelymanner or at all,including the possibilitythat a governmentalentity or regulatory body may delay or refuse to grant approval for the consummation of the transaction;Gileads ability to initiate,progress or complete clinical trials within currently anticipatedtimefra

6、mes or at all,the possibility of unfavorable results from ongoing and additional clinical trials and the risk that safety and efficacy data from clinical trials may not warrant further developmentof Gileads product candidates or the product candidates of Gileads strategic partners;Gileads ability to